298 related articles for article (PubMed ID: 7511901)
1. Pharmacological action of zotepine and other antipsychotics on central 5-hydroxytryptamine receptor subtypes.
Czyrak A; Skuza G; Rogóz Z; Frankiewicz T; Maj J
Arzneimittelforschung; 1994 Feb; 44(2):113-8. PubMed ID: 7511901
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors.
Czyrak A; Jaros T; Moryl E; Maj J
Pharmacopsychiatry; 1993 Mar; 26(2):53-8. PubMed ID: 7690975
[TBL] [Abstract][Full Text] [Related]
3. Roxindole, a dopamine autoreceptor agonist with a potential antidepressant activity. II. Effects on the 5-hydroxytryptamine system.
Maj J; Kołodziejczyk K; Rogóz Z; Skuza G
Pharmacopsychiatry; 1997 Mar; 30(2):55-61. PubMed ID: 9131725
[TBL] [Abstract][Full Text] [Related]
4. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
5. [A study on the pharmacological properties of atypical antipsychotic drugs: in vivo dopamine and serotonin receptor occupancy by atypical antipsychotic drugs in the rat brain].
Matsubara R
Hokkaido Igaku Zasshi; 1993 Jul; 68(4):570-82. PubMed ID: 7687976
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
[TBL] [Abstract][Full Text] [Related]
8. [Behavioural effects of 8-OH-DPAT, a 5-HT1A agonist in rats and effects on the behaviour of antimanic drugs].
Uchitomi Y; Yamawaki S
Yakubutsu Seishin Kodo; 1987 Sep; 7(3):383-92. PubMed ID: 2894736
[TBL] [Abstract][Full Text] [Related]
9. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
[TBL] [Abstract][Full Text] [Related]
10. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice.
Berendsen HH; Broekkamp CL
Br J Pharmacol; 1990 Nov; 101(3):667-73. PubMed ID: 2150180
[TBL] [Abstract][Full Text] [Related]
11. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
Haleem DJ; Samad N; Haleem MA
Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
[TBL] [Abstract][Full Text] [Related]
12. EMD 57445, the selective sigma receptor ligand, has no effect on the 5-hydroxytryptamine system.
Skuza G; Rogóz Z; Gołembiowska K
Pol J Pharmacol; 1997; 49(6):489-93. PubMed ID: 9566054
[TBL] [Abstract][Full Text] [Related]
13. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.
Ninan I; Kulkarni SK
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):603-8. PubMed ID: 10669905
[TBL] [Abstract][Full Text] [Related]
14. Differential induction of 5-HT1A-mediated responses in vivo by three chemically dissimilar 5-HT1A agonists.
Scott PA; Chou JM; Tang H; Frazer A
J Pharmacol Exp Ther; 1994 Jul; 270(1):198-208. PubMed ID: 8035316
[TBL] [Abstract][Full Text] [Related]
15. The effect of repeated treatment with oxaprotiline enantiomers on central 5-HT receptor subpopulations.
Dereń-Wesołek A; Maj J
Pol J Pharmacol; 1993; 45(2):133-50. PubMed ID: 8401766
[TBL] [Abstract][Full Text] [Related]
16. S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol.
Millan MJ; Brocco M; Gobert A; Schreiber R; Dekeyne A
J Pharmacol Exp Ther; 1999 Mar; 288(3):1002-14. PubMed ID: 10027837
[TBL] [Abstract][Full Text] [Related]
17. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Leysen JE; Janssen PM; Megens AA; Schotte A
J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
[TBL] [Abstract][Full Text] [Related]
18. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
[TBL] [Abstract][Full Text] [Related]
19. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
20. Some pharmacological properties of new analogs of MP 3022, the 5-HT1A receptor antagonist.
Chojnacka-Wójcik E; Kłodzińska A; Tatarczyńska E; Paluchowska MH
Pol J Pharmacol; 1999; 51(5):405-13. PubMed ID: 10817541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
